Search

Your search keyword '"Karki, Sandip"' showing total 7 results
Start Over Author "Karki, Sandip"
7 results on '"Karki, Sandip"'

1. Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities

Author

Bashyal, Krishna Prasad, primary, Shah, Sangam, additional, Ghimire, Calvin, additional, Balmuri, Shravya, additional, Chaudhary, Pradip, additional, Karki, Sandip, additional, Poudel, Anuj Krishna, additional, Pokharel, Ashbina, additional, Devarkonda, Vishal, additional, and Hayat, Samina, additional

Published
2024
Full Text
View/download PDF

4. Systematic Review and Meta-Analysis: Can We Compare Direct Oral Anticoagulants to Warfarin in Patients With Atrial Fibrillation and Bio-Prosthetic Valves?

Author

Adhikari, Govinda, primary, Baral, Nischit, additional, Rauniyar, Rohit, additional, Karki, Sandip, additional, Abdelazeem, Basel, additional, Savarapu, Pramod, additional, Isa, Sakiru, additional, Khan, Hafiz Muhammad Waqas, additional, Khan, Mahin R, additional, and Changezi, Hameem U, additional

Published
2021
Full Text
View/download PDF

7. Meta-analysis examining phosphodiesterase-5 inhibitors in heart failure with preserved ejection fraction.

Author

Adhikari G, Baral N, Rauniyar R, Tse G, Karki S, Abdelazeem B, Gergis K, Savarapu P, Isa S, Sud P, and Kunadi A

Abstract

Patients with heart failure with preserved ejection fraction have reduced cyclic guanosine 3',5'-monophosphate (cGMP) levels compared to those with reduced ejection fraction. Phosphodiesterase-5 inhibitors may play a cardioprotective role by potentiating the cGMP pathway. To address this question, we conducted a systematic search for randomized trials using the electronic databases of PubMed, Embase, and Google Scholar and used RevMan (version 5.4) for the data analysis. We included 221 subjects in the phosphodiesterase group (mean age 69.2 ± 3.43 years; 58.82% male) and 202 subjects in the control group (mean age 70.4 ± 4.96 years; 53.46% male). The mean follow-up duration was 5.85 ± 3.43 months. The pooled results showed no significant differences in peak oxygen consumption, 6-minute walking distance, mitral annular E/e' ratio, left ventricular ejection fraction, mean pulmonary artery pressure, pulmonary artery systolic pressure, and pulmonary vascular resistance between the phosphodiesterase group and the control group., (Copyright © 2022 Baylor University Medical Center.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results